Cytek BioSciences could be valued at more than $2.3 billion as IPO terms have been set

Cytek BioSciences Inc.
CTKB,
has set terms for its initial public offering, in which the California-based cell analysis company could be valued at up to $2.35 billion. A total of 14.56 million shares are being offered in the IPO, which is expected to…

Click here to view the original article.